Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 6:08 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 755 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Raised Intraocular Pressure Clear all

Conditions: Ocular Hypertension, Suspect Glaucoma
Interventions: Rocklatan (Netarsudil 0.02%/ latanoprost 0.005), Latanoprost (0.005%); Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 4
States / cities: Baltimore, Maryland • Columbia, Maryland • Silver Spring, Maryland

Conditions: Glaucoma
Interventions: MEMS cap; Device
Lead sponsor: Robin, Alan L., M.D.; Individual
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Glaucoma
Interventions: Efficacy-patient navigator to improve follow-up adherence, Office-Based Usual Care; Behavioral
Lead sponsor: Wills Eye; Other
Eligibility: 50 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Intraocular Pressure, Glaucoma
Interventions: IOP with Goldmann Applanation Tonometer, IOP with comparator ORA G3 and ic100 tonometers, IOP with Tono-Vera Tonometer; Device
Lead sponsor: Reichert, Inc.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Glaucoma
Interventions: Not listed
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 40 Years to 85 Years
Enrollment: 249 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2031
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Glaucoma, Ocular Hypertension
Interventions: Formulation E1 of L-PPDS, Formulation E2 of L-PPDS; Drug
Lead sponsor: Mati Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Menlo Park, California

Conditions: Glaucoma
Interventions: brimonidine 0.15%; Drug
Lead sponsor: Massachusetts Eye and Ear Infirmary; Other
Eligibility: 35 Years to 80 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Glaucoma
Interventions: Not listed
Lead sponsor: Wills Eye; Other
Eligibility: 40 Years to 80 Years
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Primary Open Angle Glaucoma
Interventions: Canaloplasty using the iTrack microcatheter with Healon GV Pro, Canaloplasty using the Omni surgical system with Healon GV Pro, Canaloplasty using the iTrack microcatheter with Healon Pro, Canaloplasty using the Omni surgical system with Healon Pro; Device
Lead sponsor: Nova Eye, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 7
States / cities: Glendale, Arizona • Beverly Hills, California • Orange, California + 4 more

Conditions: Glaucoma, Open-Angle
Interventions: Negative Pressure Treatment via the Mercury Multi-Pressure Dial; Device
Lead sponsor: Equinox; Industry
Eligibility: 22 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 3
States / cities: Chicago, Illinois • Sioux Falls, South Dakota • San Antonio, Texas

Conditions: Glaucoma
Interventions: Observation only; Other
Lead sponsor: Peregrine Ophthalmic; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Goose Creek, South Carolina

Conditions: Glaucoma
Interventions: Bimatoprost 0.03%, Travoprost 0.004%, Timolol 0.5%; Drug
Lead sponsor: Innovative Medical; Industry
Eligibility: 18 Years and older
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Primary Open Angle Glaucoma
Interventions: Hydrus Microstent, Cataract surgery, Monofocal IOL; Device · Procedure
Lead sponsor: Alcon Research; Industry
Eligibility: 45 Years and older
Enrollment: 545 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 22
States / cities: Irvine, California • Sacramento, California • Loveland, Colorado + 19 more

Conditions: Open Angle Glaucoma, Ocular Hypertension, Glaucoma, Open Angle, Pseudo-exfoliative, Pigment Dispersion Syndrome, Glaucoma
Interventions: Selective Laser Trabeculoplasty, Neodymium:Yttrium Aluminum Garnet (YAG) laser; Procedure · Device
Lead sponsor: Temple University; Other
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 2
States / cities: Wilmington, Delaware • Thorndale, Pennsylvania

Conditions: Glaucoma, Open Angle Glaucoma, Ocular Hypertension
Interventions: PhXA41, timolol; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 40 Years and older
Enrollment: 268 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1993 – 1994
U.S. locations: 17
States / cities: La Jolla, California • Los Angeles, California • Gainesville, Florida + 12 more

Conditions: Primary Open Angle Glaucoma
Interventions: Not listed
Lead sponsor: University of Cincinnati; Other
Eligibility: 0 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Glaucoma Open-Angle Primary, Glaucoma, Open Angle Glaucoma, Glaucoma, Open-Angle
Interventions: Mitomycin C; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 20 Years to 85 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 4
States / cities: Arcadia, California • Fountain Valley, California • Los Angeles, California + 1 more

Conditions: Glaucoma
Interventions: Selective laser trabeculoplasty; Procedure
Lead sponsor: West Virginia University; Other
Eligibility: 30 Years and older
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Glaucoma Open-Angle Primary, Ocular Hypertension
Interventions: H-1337 0.6%, H-1337 1.0%, H-1337 Placebo, Timolol 0.5%; Drug
Lead sponsor: D. Western Therapeutics Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 9
States / cities: Glendale, California • Colorado Springs, Colorado • Lakeland, Florida + 6 more

Conditions: Glaucoma, Quality of Life
Interventions: Clinical evaluation, Performance based measures, Subjective measures of vision-related quality of life; Other
Lead sponsor: Wills Eye; Other
Eligibility: 18 Years to 80 Years
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Glaucoma
Interventions: Virtual Reality Visual Field, Standard Automated Perimetry; Device · Diagnostic Test
Lead sponsor: University of Miami; Other
Eligibility: 1 Year to 90 Years
Enrollment: 287 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Glaucoma
Interventions: rtACS Stimulation, Sham Intervention; Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 50 Years to 70 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Open Angle Glaucoma, Ocular Hypertension
Interventions: Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution, Latanoprost 0.005% Ophthalmic Solution; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Primary Open Angle Glaucoma
Interventions: Not listed
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 133 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: La Jolla, California

Search by objective public record fields.

Measuring the Effects of Netarsudil, Latanoprost, and Combination Therapy on Episcleral and Retinal Blood Flow in Ocular Hypertension and Glaucoma Suspects

Observational Study of How Patients Take Eye Drops

Comparison Study of Glaucoma Eye Care Follow-Up Adherence in a High Risk Population

Comparison of Intraocular Pressure Measurements Between Reichert Tono-Vera Tonometer and Goldmann Tonometry

Functional and Structural Imaging for Glaucoma

A Study of Different Formulations of the L-PPDS in Subjects With OH or OAG

Effect of Alphagan on Retinal Blood Flow Autoregulation and Motion Detection in Patients With Normal Pressure Glaucoma

Will Listening to Music Make it Easier to Take a Visual Field Test?

Multicenter Ab-interno Glaucoma Study Investigating Canaloplasty

Negative Pressure Applied by the Equinox MPD for Severe Open Angle Glaucoma

Open Label Extension of LipoLat-CS202

Bimatoprost Monotherapy vs. Dual Therapy With Travoprost and Timolol in Patients With Glaucoma and Ocular Hypertension

Hydrus® Microstent New Enrollment Post-Approval Study

180 Degree vs. 360 Degree Selective Laser Trabeculoplasty as Initial Therapy for Glaucoma

A 6 Month Study Comparing Latanoprost With Timolol in Patients With Open Angle Glaucoma or Ocular Hypertension

Results of Ocular Compression and Suture Release in Trabeculectomy and Combined Surgery

Comparing Preoperative Injection of Mitomycin-C vs. Intraoperative Injection of Mitomycin-C vs. Topical Application of Mitomycin-C (Conventional Use) in Trabeculectomy

Glaucoma Management in the African-Derived Developing World Using Trabeculoplasty

Study of Safety and Efficacy of H-1337 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

How Has Glaucoma Affected Your Quality of Life?

Patient Performance on Virtual Reality Visual Field Devices as Compared to Standard of Care

A Study Using Transorbital Alternating Current Stimulation for People With Glaucoma

24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients

STudy to Assess Rapid Disease Progression by Clinical and Genetic Factors In Glaucoma patientS That Are High Risk